What does the future of treatment for C3 Glomerulopathy (C3G) look like?

Dr. Nicole van de Kar (Radboud University Medical Center, The Netherlands) unpacks the pathophysiology of C3G, from genetic and autoantibody factors to the central role of the alternative pathway. She explores the limits of current C5 therapies and the potential of new strategies targeting C3 activation that could reshape patient care worldwide.

This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).

This series was supported by Apellis and Sobi.